Effects of deferiprone: A Synthesis of Findings from 21 Studies
- Home
- Effects of deferiprone
This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of deferiprone: A Synthesis of Findings from 21 Studies", please consult your doctor.
For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
Major Research Findings
Deferiprone, an oral iron chelator, has been shown to be effective in reducing iron overload in patients with β-thalassemia. 17 found that combined therapy with deferiprone and deferoxamine significantly reduced iron load in the liver and heart of patients with β-thalassemia. 20 suggested that deferiprone may be more effective than deferoxamine in preventing heart disease and extending survival in patients with β-thalassemia. In addition, 19 demonstrated that deferiprone is an effective and safe iron chelator in Pakistani patients with β-thalassemia. These studies suggest that deferiprone is a promising drug for the treatment of iron overload.
6 showed that deferiprone improved cardiac function and calcium regulation in a mouse model of iron overload. However, the study concluded that further research is needed to clarify the effect of deferiprone on calcium regulation. 12 found that combined therapy with deferiprone and deferoxamine improved right ventricular function in patients with β-thalassemia. 15 suggests that deferiprone may affect the oxygen affinity of β-thalassemia hemoglobin, indicating a potential impact on hemoglobin structure and function. However, 13 suggests that deferiprone may promote iron uptake in hepatocytes, highlighting the complex mechanism of action.
18 reported a dramatic improvement in symptoms and myocardial function in a patient with end-stage heart failure from β-thalassemia who was treated with deferiprone in addition to desferrioxamine. This study suggests that deferiprone may be a viable therapeutic option for patients with end-stage heart failure. 9 found that the pharmacokinetics of deferiprone is affected by renal function, suggesting the need to adjust the dose of deferiprone in patients with impaired kidney function. Furthermore, 21 suggested that deferiprone may affect the immune status of patients with β-thalassemia. More research is needed to understand the impact of deferiprone on the immune system.
1 found that deferiprone reduced brain damage caused by lead poisoning in mice. This study suggests that deferiprone may be a potential treatment option for lead poisoning. 8 showed that deferiprone and deferoxamine reduced iron accumulation in the kidneys of iron-overloaded mice, but the two drugs worked through different mechanisms. This study highlights the complex mechanism of action of deferiprone and calls for further research. In addition, 11 showed that deferiprone reduced spleen damage caused by aluminum poisoning. 10 found that deferiprone reduced iron accumulation in the liver and heart of iron-overloaded mice, indicating its potential as a treatment option for iron overload.
7 compared the iron chelation effects of deferoxamine, deferasirox, and a combination of deferoxamine and deferiprone on liver and heart iron load measured by T2* MRI. This study found that combining deferiprone with deferoxamine improved iron reduction in the heart and liver. 14 found that deferiprone did not promote the growth of *Klebsiella pneumoniae*, a bacteria often found in patients with thalassemia, suggesting that deferiprone does not increase the risk of infection. 16 demonstrated that deferiprone inhibited the growth of *Vibrio vulnificus*, a bacteria that can cause serious infections. This finding suggests that deferiprone may have antibacterial properties against certain bacteria.
5 found that deferiprone reduced the toxicity of iron overload on osteoblasts but could not fully prevent their death. This suggests that deferiprone may need to be used in combination with other therapies to treat iron overload-induced osteoporosis. 4 found that deferiprone reduced the toxicity of lead poisoning on testes in mice. This study suggests that deferiprone may be a potential treatment option for lead poisoning. 2 found that deferiprone reduced the accumulation of cadmium in the brain of mice exposed to cadmium. This study suggests that deferiprone may be a potential treatment option for cadmium poisoning. Finally, 3 found that deferiprone reduced kidney damage caused by lead poisoning but salinomycin was more effective. This study suggests that the effectiveness of deferiprone in treating lead poisoning may be limited compared to other drugs.
Benefits and Risks
Benefits Summary
Deferiprone may be an effective drug for treating iron overload. Deferiprone may help prevent or reduce damage to organs such as the heart and liver by reducing iron accumulation in these organs. Deferiprone may also be effective in treating heavy metal poisoning, such as lead and cadmium poisoning. In addition, deferiprone may have antibacterial properties against certain bacteria.
Risks Summary
Deferiprone can cause side effects. Some common side effects of deferiprone include nausea, vomiting, abdominal pain, rash, joint pain, anemia, and liver dysfunction. Deferiprone may also affect kidney function. Doses may need to be adjusted for patients with impaired kidney function. Furthermore, deferiprone may affect immune status. More research is needed to understand the impact of deferiprone on the immune system.
Comparison between Studies
Commonalities between Studies
Many studies suggest that deferiprone is an effective treatment for iron overload. These studies show that deferiprone is effective in reducing iron accumulation in the heart and liver. Additionally, deferiprone may also be effective in treating heavy metal poisoning such as lead poisoning and cadmium poisoning.
Differences between Studies
The mechanism of action and side effects of deferiprone vary between studies. Some studies suggest that deferiprone may promote iron uptake. There are also variations in reported side effects. These differences may be due to different disease types, patient characteristics, deferiprone doses, and research methodologies.
Consistency and Contradictions in Results
The results of studies on the effects of deferiprone have shown both consistency and contradictions. Many studies suggest that deferiprone is effective for treating iron overload, but there are variations in the reported mechanism of action and side effects. The mechanism of action of deferiprone is complex and requires further research.
Real-World Application Considerations
Deferiprone is a potential drug for treating iron overload. However, deferiprone can cause side effects. It's important to follow your doctor's instructions if you are taking deferiprone. Additionally, avoid self-adjusting your dose or discontinuing medication without consulting your doctor. If you have concerns about the side effects of deferiprone, consult your doctor.
Limitations of Current Research
The research on deferiprone's effects is still limited. Further research is needed to understand the long-term effects and safety of deferiprone. More detailed research is also needed on the mechanism of action and side effects of deferiprone. Additionally, the effects of deferiprone may vary between patients. Therefore, further research is needed to evaluate the effects of deferiprone on an individual basis.
Future Research Directions
Further research is needed to better understand the effects of deferiprone. Long-term effects and safety of deferiprone should be investigated. More detailed research on the mechanism of action and side effects is also necessary. Finally, research on evaluating the effects of deferiprone on an individual basis is crucial.
Conclusions
Deferiprone shows potential as a treatment for iron overload. However, it's important to be aware of the potential side effects. Always follow your doctor's instructions when taking deferiprone. The research on the effects of deferiprone is still limited, and more research is needed to understand the long-term effects and safety of this drug.
Benefit Keywords
Risk Keywords
Article Type
Author: PetrovaEmilia, GluhchevaYordanka, PavlovaEkaterina, VladovIvelin, DorkovPeter, SchaierMartin, Pashkunova-MarticIrena, HelbichThomas H, KepplerBernhard, IvanovaJuliana
Language : English
Author: PetrovaEmilia, Pashkunova-MarticIrena, SchaierMartin, GluhchevaYordanka, PavlovaEkaterina, HelbichThomas H, KepplerBernhard, IvanovaJuliana
Language : English
Author: GluhchevaYordanka, Pashkunova-MarticIrena, SchaierMartin, VladovIvelin, StoykovaSilviya, PetrovaEmilia, PavlovaEkaterina, DorkovPeter, HelbichThomas H, KepplerBernhard, IvanovaJuliana
Language : English
Author: PavlovaEkaterina, Pashkunova-MarticIrena, SchaierMartin, PetrovaEmilia, GluhchevaYordanka, DorkovPeter, HelbichThomas H, KepplerBernhard, KoellenspergerGunda, IvanovaJuliana
Language : English
Author: LertsuwanKornkamon, NammultriputtarKetsaraporn, NanthawuttiphanSupanan, TannopNatnicha, TeerapornpuntakitJarinthorn, ThongbunchooJirawan, CharoenphandhuNarattaphol
Language : English
Author: KhamseekaewJuthamas, KumfuSirinart, PaleeSiripong, WongjaikamSuwakon, SrichairatanakoolSomdet, FucharoenSuthat, ChattipakornSiriporn C, ChattipakornNipon
Language : English
Author: AnsariShahla, AzarkeivanAzita, Miri-AliabadGhasem, YousefianSaeed, RostamiTahereh
Language : English
Author: YatmarkParanee, MoralesNoppawan Phumala, ChaisriUrai, WichaiyoSurasak, HemstapatWarinkarn, SrichairatanakoolSomdet, SvastiSaovaros, FucharoenSuthat
Language : English
Author: FradetteCaroline, PichetteVincent, SicardÉric, StilmanAnne, JayashankarShalini, TsangYu Chung, SpinoMichael, TrictaFernando
Language : English
Author: YatmarkParanee, MoralesNoppawan Phumala, ChaisriUrai, WichaiyoSurasak, HemstapatWarinkarn, SrichairatanakoolSomdet, SvastiSaovaros, FucharoenSuthat
Language : English
Author: SivakumarS, KhatiwadaChandra Prasad, SivasubramanianJ
Language : English
Author: AlpenduradaFrancisco, SmithGill C, CarpenterJohn-Paul, NairSunil V, TannerMark A, BanyaWinston, DessiCarlo, GalanelloRenzo, WalkerJohn Malcolm, PennellDudley J
Language : English
Effects of deferasirox and deferiprone on cellular iron load in the human hepatoma cell line HepaRG.
Author: GaboriauFrançois, LerayAnne-Marie, RopertMartine, GouffierLucie, CannieIsabelle, TroadecMarie-Bérengère, LoréalOlivier, BrissotPierre, LescoatGérard
Language : English
Author: ChanGodfrey Chi-Fung, ChanShing, HoPak-Leung, HaShau-Yin
Language : English
Author: Moosavi-MovahediA A, MousavyS J, DivsalarA, BabaahmadiA, KarimianK, ShafieeA, KamarieM, PoursasanN, FarzamiB, RiaziG H, HakimelahiG H, TsaiF Y, AhmadF, AmaniM, SabouryA A
Language : English
Author: NeupaneGanesh Prasad, KimDong-Min
Language : English
Author: TsironiMaria, AssimakopoulosGeorge, PolonofiKaterina, RigakiKalliopi, AessoposAthanassios
Language : English
Author: PorcuMaurizio, LandisNovella, SalisStefano, CordaMarco, OrrùPierpaolo, SerraEmanuela, UsaiBarbara, MattaGildo, GalanelloRenzo
Language : English
Author: AyyubMuhammad, AliWaqar, AnwarMasood, WaqarAmin, KhanM Naeem, IjazAamir, HussainTassawar, HussainShujaat
Language : English
Author: PigaAntoni, GagliotiCarmen, FogliaccoEugenia, TrictaFernando
Language : English
Author: Del VecchioGiovanni Carlo, SchettiniFederico, PiacenteLaura, De SantisAttilio, GiordanoPaola, De MattiaDomenico
Language : English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.